Individualized immunosuppression in transplant patients: Potential role of pharmacogenetics

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2012, Pages 63-72

  Abboud, Hamid ^a   MacPhee, Iain A M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CYP3A5; Immunosuppression; Pharmacogenetics; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A5; DACLIZUMAB; ECULIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABCB1 GENE; ACUTE GRAFT REJECTION; AGRANULOCYTOSIS; ALLELE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CATARACT; CYP3A4 GENE; CYP3A5 GENE; CYTOKINE RELEASE SYNDROME; DIABETES MELLITUS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GENE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE INTOLERANCE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEREDITY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMPDH1 GENE; INFECTION; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCELE; MAINTENANCE THERAPY; MICROCYTIC ANEMIA; MOUTH ULCER; NEPHROTOXICITY; OSTEOPOROSIS; PHARMACODYNAMICS; PHARMACOGENETICS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UGT1A9 GENE; WOUND HEALING IMPAIRMENT;

EID: 84865133690     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S21743     Document Type: Article

References (74)

1. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant. 2011;11:1226-1235.
2. Hanaway MJ, Woodle ES, Mulgaonkar S, etal. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364:1909-1919.
3. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
4. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
5. Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant. 2009;9:160-168.
6. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8:307-316.
7. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, etal. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol. 2002;13:1365-1373.
8. Rostaing L, Cantarovich D, Mourad G, etal. Corticosteroid-free immu- nosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation. 2005;79:807-814.
9. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van VP. A prospective, randomized, double-blind, placebo-controlled multi- center trial comparing early (7day) corticosteroid cessation versus long- term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564-577.
10. Kumar MS, Heifets M, Moritz MJ, etal. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation. 2006;81:832-839.
11. Arnol M, de Mattos AM, Chung JS, Prather JC, Mittalhenkle A, Norman DJ. Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation. 2008;86:1844-1848.
12. Rike AH, Mogilishetty G, Alloway RR, et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal t{stroke}ransplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant. 2008;22:229-235.
13. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet. 1983;2:986-989.
14. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481-508.
15. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol. 2006;17(1):305-312.
16. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557-565.
17. Snanoudj R, Royal V, Elie C, etal. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low- dose cyclosporine therapy. Am J Transplant. 2011;11:2635-2646.
18. Ekberg H, Grinyo J, Nashan B, etal. Cyclosporine sparing with myco-phenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007;7:560-570.
19. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810.
20. Artz MA, Boots JM, Ligtenberg G, etal. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol. 2003;14:1880-1888.
21. Sarnak MJ, Levey AS, Schoolwerth AC, etal. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169.
22. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-2575.
23. Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, de Fijter JW. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int. 2003;64: 1027-1034.
24. Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data. Transplantation. 2007;83: 582-587.
25. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharma- cokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22(Suppl B):B101-B121.
26. Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1999;68:1100-1106.
27. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77:1555-1561.
28. Langer RM, Kahan BD. Incidence, therapy, and consequences of lym-phocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation. 2002;74:804-808.
29. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580-590.
30. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int. 2006;70:1019-1025.
31. Campistol JM, Eris J, Oberbauer R, etal. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-589.
32. Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosup- pressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics. 2008;9:585-596.
33. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997;63:39-47.
34. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 2000;69:2405-2409.
35. Vincenti F, Charpentier B, Vanrenterghem Y, etal. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10: 535-546.
36. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant. 2011;11:1359-1367.
37. Walsh RC, Brailey P, Girnita A, etal. Early and late acute antibody- mediated rejection differ immunologically and in response to protea- some inhibition. Transplantation. 2011;91:1218-1226.
38. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11:2405-2413.
39. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16:3015-3026.
40. Sagoo P, Perucha E, Sawitzki B, etal. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120:1848-1861.
41. Newell KA, Asare A, Kirk AD, etal. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120:1836-1847.
42. Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation. 2010;89: 1417-1423.
43. Glander P, Sommerer C, Arns W, etal. Pharmacokinetics and pharmaco- dynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol. 2010;5:503-511.
44. Bremer S, Mandla R, Vethe NT, et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation. 2008;85:55-61.
45. Bohler T, Nolting J, Kamar N, etal. Validation of immunological bio- markers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit. 2007;29:77-86.
46. Kowalski RJ, Post DR, Mannon RB, etal. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-668.
47. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens. 2002;11:657-663.
48. Clase CM, Mahalati K, Kiberd BA, etal. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients moni- tored by absorption profiling. Am J Transplant. 2002;2:789-795.
49. Undre NA, van Hoof J, Christiaans M, et al. Low systemic expo- sure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298.
50. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the preven- tion of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
51. Evans WE. Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics. 2002;12:421-423.
52. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynam- ics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623-653.
53. Staatz CE, Tett SE. Pharmacokinetic considerations relating to tacroli- mus dosing in the elderly. Drugs Aging. 2005;22:541-557.
54. Vadivel N, Garg A, Holt DW, Chang RW, Macphee IA. Tacrolimus dose in black renal transplant recipients. Transplantation. 2007;83: 997-999.
55. MacPhee IAM, Fredericks S, Tai T, etal. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002;74:1486-1489.
56. Ng FL, Holt DW, Macphee IA. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother. 2007;8:2045-2058.
57. Macphee IA. Use of pharmacogenetics to optimize immunosuppressive therapy. Ther Drug Monit. 2010;32:261-264.
58. Hesselink DA, van Schaik RH, van Agteren M, etal. CYP3A5geno- type is not associated with a higher risk of acute rejection in tacroli- mus-treated renal transplant recipients. Pharmacogenet Genomics. 2008;18:339-348.
59. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tac- rolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721-726.
60. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57: 1574-1583.
61. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011;12:1281-1291.
62. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72:948-957.
63. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab. 2005;6:369-383.
64. Press RR, Ploeger BA, den HJ, etal. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol. 2010;66:579-590.
65. Fredericks S, Jorga A, MacPhee IAM, etal. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2measurements. Clin Transplant. 2007;21:252-257.
66. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose require ments and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12:1383-1396.
67. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005;5:595-603.
68. Le Meur Y, Djebli N, Szelag JC, etal. CYP3A5*3influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther. 2006;80:51-60.
69. Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos. 2007;29:1-5.
70. Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P. CYP3A5genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplan- tation. 2011;91:652-656.
71. van Schaik RH, van AM, de Fijter JW, et al. UGT1A9-275T.A/- 2152C.T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319-327.
72. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2007;83:711-717.
73. Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18:307-315.
74. Capron A, Mourad M, de MM, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11:703-714.